Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
GEVA > SEC Filings for GEVA > Form 8-K on 9-Jun-2014All Recent SEC Filings

Show all filings for SYNAGEVA BIOPHARMA CORP

Form 8-K for SYNAGEVA BIOPHARMA CORP


9-Jun-2014

Change in Directors or Principal Officers, Submission of Matters to a Vot


Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Synageva BioPharma Corp. (the "Company") held its Annual Meeting of Stockholders (the "Annual Meeting") on June 4, 2014. At the Annual Meeting, the Company's stockholders approved the Company's 2014 Equity Incentive Plan (the "Equity Plan").

A brief description of the terms and conditions of the Equity Plan is set forth under the heading "Proposal No. 3 - To Approve the Company's 2014 Equity Incentive Plan" in the Company's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 23, 2014, which description is incorporated herein by reference. The description of the Equity Plan is qualified in its entirety by reference to the full text of the Equity Plan, a copy of which is attached hereto as Exhibit 10.1.



Item 5.07 Submission of Matters to a Vote of Security Holders.

At the Annual Meeting, the Company's stockholders voted on the following matters:

Proposal 1: Stockholders elected each nominee for director, each to serve until the next annual meeting of stockholders or until his successor is duly elected and qualified:

           Name                    For          Withheld      Broker Non-Votes
           Felix J. Baker        28,944,229       487,547               392,885
           Stephen R. Biggar     29,116,464       315,312               392,885
           Stephen R. Davis      29,312,771       119,005               392,885
           Thomas R. Malley      29,353,677        78,099               392,885
           Barry Quart           29,346,759        85,017               392,885
           Sanj K. Patel         29,310,989       120,787               392,885
           Thomas J. Tisch       29,354,426        77,350               392,885
           Peter Wirth           29,346,877        84,899               392,885

Proposal 2: Stockholders approved, on a non-binding advisory basis, the compensation of the Company's named executive officers:

For Against Abstaining Broker Non-Votes 28,920,302 509,025 2,449 392,885

Proposal 3: Stockholders approved the Company's 2014 Equity Incentive Plan:

For Against Abstaining Broker Non-Votes 25,819,602 3,610,278 1,896 392,885


Proposal 4: Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2014:

For Against Abstaining 29,815,171 8,963 527



Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

10.1 Synageva BioPharma Corp. 2014 Equity Incentive Plan.


  Add GEVA to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for GEVA - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.